Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-CAR T cell Therapy in Pediatric Hematological Malignancies
NCT06326463Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 2024
- Primary completion
- Jul 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD70-specific CAR-T cells in hematological malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 3 more, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2024; status: recruiting.
02
Drugs
CD70-specific CAR-T cells
03
Conditions
hematological malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT06326463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326463.